At present, Myriad Genetics, Inc (MYGN) has a stock price of $5.15. In the previous session, the stock saw a rise, peaking at $18.0 after an opening price of $5.17. The day’s lowest price was $3.5, and it closed at $3.87.
Myriad Genetics, Inc experienced a rather shaky stock market performance.
52-week price history of MYGN Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Myriad Genetics, Inc’s current trading price is -82.42% away from its 52-week high, while its distance from the 52-week low is 36.97%. The stock’s price range during this period has spanned from $3.76 to $29.30. In the Healthcare sector, the Myriad Genetics, Inc’s shares surpassed a trading volume of approximately 7.55 million for the day, which was noticeably higher compared to the average daily volume of 9.2.13 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Myriad Genetics, Inc (MYGN) has experienced a quarterly decline of -29.16% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 474.74M and boasts a workforce of 2700 employees.
A Closer Look at Analysts’ Ratings for Myriad Genetics, Inc
As of right now, 1 analyst is rating Myriad Genetics, Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 9 analysts are recommending to HOLD this stock, 2 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.07, with a change in price of -4.57. Similarly, Myriad Genetics, Inc recorded 1,926,623 in trading volume during the last 100 days, posting a change of -47.16%.
Examining MYGN’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for MYGN stands at 0.40. Similarly, the long-term debt-to-equity ratio is also 0.22.
MYGN Stock Stochastic Average
Today, Myriad Genetics, Inc’s raw stochastic average for the past 50 days stands at 65.94%, indicating a rise from the raw stochastic average of the last 20 days, which was 65.94%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 27.29% and 13.72% respectively.
MYGN Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. Year to date metric has recorded a loss of -80.67%.However, over the last six months, we can see a stronger performance of -58.50%. Over the last 30 days, the price of MYGN has leaped by -7.20%. And in the last five days, it has surged by 27.17%.
